CompanyGraph
China Isotope & Radiation Corporation
1763 · HKEX · China
Price data from its 5IR listing on FSX, quoted in EUR
circ.com.cnFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $1.09B, above the global median of $548.88M
- PositionP/E ratio is 12.1×, lower than 95% of its Medical Devices peers (median 31.99×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.81%Below 5Y avg (2.79%)
Annual Rate
HKD 0.26Paid annual
Payout Ratio
30.2%Sustainable
Payback Period
5.2 yr
Last Ex-Dividend
Oct 5, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.09BHKD903.56M · vs all stocks (USD)
Trailing P/E
12.10xvs Medical Devices peers
Revenue (TTM)
8.56BCNY1.09B · vs all stocks (USD)
Profit Margin
4.45%vs Medical Devices peers
Beta
0.4800xvs all stocks
52-Week Change
-8.16%vs all stocks
Market Capitalization
7.09BHKD903.56M · vs all stocks (USD)
Enterprise Value
9.41BHKD1.20B · vs all stocks (USD)
Trailing P/E
12.10xvs Medical Devices peers
Price to Sales (TTM)
0.6298xvs Medical Devices peers
Price to Book (MRQ)
0.7418xvs Medical Devices peers
Enterprise to Revenue
1.10xvs Medical Devices peers
Enterprise to EBITDA
6.23xvs Medical Devices peers
Profit Margin
4.45%vs Medical Devices peers
Operating Margin
15.72%vs Medical Devices peers
Return on Assets (TTM)
4.23%vs Medical Devices peers
Return on Equity (TTM)
8.23%vs Medical Devices peers
Revenue (TTM)
8.56BCNY1.09B · vs all stocks (USD)
Revenue per Share (TTM)
22.86CNYUpdated Sep 20, 2026Quarterly Revenue Growth
4.40%vs Medical Devices peers
Gross Profit (TTM)
4.24BCNY540.33M · vs all stocks (USD)
EBITDA (TTM)
1.37BCNY174.60M · vs all stocks (USD)
Net Income (TTM)
381.22MCNY48.59M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-1.20%vs Medical Devices peers
Operating Cash Flow (TTM)
919.97MCNY117.27M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
56.72MCNY7.23M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2604HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
1.81%vs all stocks
5-Year Average Dividend Yield
2.79%vs all stocks
Payout Ratio
30.23%vs Medical Devices peers
Minority Interest (Equity)
2.91BCNYFY2025 · Dec 31, 2025Revenue
7.19BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
3.57BCNYFY2025 · Dec 31, 2025Gross Profit
3.62BCNYFY2025 · Dec 31, 2025Operating Income
1.05BCNY156.49M · vs all stocks (USD)
Pre-tax Income
1.00BCNYFY2025 · Dec 31, 2025Income Tax Expense
339.58MCNYFY2025 · Dec 31, 2025Net Income
664.54MCNYFY2025 · Dec 31, 2025EBIT
1.07BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.37BCNYFY2025 · Dec 31, 2025Research & Development
301.92MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
2.33BCNYFY2025 · Dec 31, 2025Non-operating Interest Income
17.30MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
65.18MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.02CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.02CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
319.87MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
319.87MSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
-337.12MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
395.22MCNYFY2025 · Dec 31, 2025Free Cash Flow
395.19MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.47BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.00BCNYFY2025 · Dec 31, 2025Other Non-cash Items
-4.44MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.81MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-606.28MCNYFY2025 · Dec 31, 2025Capital Expenditures
28.00KCNYFY2025 · Dec 31, 2025Net Acquisitions
-28.10MCNYFY2025 · Dec 31, 2025Purchase of Investments
-70.55MCNYFY2025 · Dec 31, 2025Sale of Investments
149.88MCNYFY2025 · Dec 31, 2025Other Investing Activity
119.64MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
170.90MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.51BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.29BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-124.66MCNYFY2025 · Dec 31, 2025Other Financing Charges
34.26MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
137.06MCNYFY2025 · Dec 31, 2025Shares Outstanding
319.87MSharesUpdated Sep 20, 2026Float Shares
54.25MSharesUpdated Sep 20, 2026% Held by Insiders
32.16%vs all stocks
% Held by Institutions
8.12%vs all stocks
Total Cash (MRQ)
2.99BCNY381.18M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.98CNYUpdated Sep 20, 2026Total Debt (MRQ)
3.45BCNY439.55M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3528xvs Medical Devices peers
Current Ratio (MRQ)
1.80xvs Medical Devices peers
Book Value per Share (MRQ)
19.41CNYUpdated Sep 20, 2026Total Assets
15.72BCNY2.35B · vs all stocks (USD)
Total Current Assets
9.34BCNYFY2025 · Dec 31, 2025Total Liabilities
7.58BCNYFY2025 · Dec 31, 2025Total Non-current Assets
6.38BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
2.29BCNYFY2025 · Dec 31, 2025Total Current Liabilities
5.29BCNYFY2025 · Dec 31, 2025Cash
2.47BCNYFY2025 · Dec 31, 2025Cash Equivalents
93.94MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.56BCNYFY2025 · Dec 31, 2025Accounts Receivable
4.84BCNYFY2025 · Dec 31, 2025Inventory
1.35BCNYFY2025 · Dec 31, 2025Accounts Payable
719.02MCNYFY2025 · Dec 31, 2025Short-term Debt
923.82MCNYFY2025 · Dec 31, 2025Long-term Debt
1.80BCNYFY2025 · Dec 31, 2025Common Stock (Book)
319.88MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
8.13BCNY1.21B · vs all stocks (USD)
52-Week Low
13.06HKDUpdated Sep 20, 202652-Week High
25.00HKDUpdated Sep 20, 202652-Week Change
-8.16%vs all stocks
Beta
0.4800xvs all stocks
50-Day MA
16.17HKDUpdated Sep 20, 2026200-Day MA
19.04HKDUpdated Sep 20, 2026Avg 10-Day Volume
190.80KSharesUpdated Sep 20, 2026Avg 30-Day Volume
97.65KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
1.19CNYUpdated Sep 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Near 52W Low With Profitability And FCF
Within 1% of its 52-week low, profitable three years, and capex takes less of its cash flow than at most of its peers.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 12.1×, lower than 95% of its Medical Devices peers (median 31.99×)Notable
P/E ratio: 12.10Industry median: 31.99Industry P5: 13.07Peers compared: 102
Financial Health
Altman Z-Score 1.47: grey zoneSignificant
Altman Z-Score: 1.47
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $1.09B, above the global median of $548.88MNotable
Revenue (USD): 1,091,717,599.195Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rigel Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ceribell, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cloudbreak Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jade Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Alumis Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Foxtons Group plc
1 interpretationNear 52W Low With Profitability And FCF
The Foschini Group Ltd.
1 interpretationNear 52W Low With Profitability And FCF
Jiangsu Zhengdan Chemical Co., Ltd.
1 interpretationNear 52W Low With Profitability And FCF